Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

The most widely studied targeted therapies for the third- and further-line treatment of NSCLC are EGFR inhibitors: gefitinib, erlotinib, cetuximab and afatinib (Table 3). The most important predictive ...

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

Panelists discuss how NCCN guidelines are expected to incorporate quadruplet-based regimens as reasonable treatment approaches for transplant-ineligible patients, while emphasizing the need for ...

Please provide your email address to receive an email when new articles are posted on . The combination of amivantamab-vmjw and lazertinib extended OS by more than 1 year. Previously reported results ...

For gout, xanthine oxidase (XO) inhibitors are the choice for first-line urate-lowering therapy (ULT) according to the 2020 American College of Rheumatology Guideline for the Management of Gout, which ...

Please provide your email address to receive an email when new articles are posted on . In an interview with Healio, Kushner said these findings, presented at The Liver Meeting, suggest “perhaps ...

Pfizer has rolled out detailed trial data suggesting Tukysa could be part of a new first-line treatment to delay the progression of HER2-positive breast cancer. The current standard of care for the ...